Figure 12 displays a forest plot of studies reporting the weighted mean difference in plasma glucose between the intervention group and control group. Data from Figure 12 are presented in Appendix C, Tables 1 and 2. This figure is described further in the section “Results: Key Question 3: Behaviorally-based Interventions: Glucose Tolerance” as follows: “Twelve of 38 trials reported glucose tolerance. When eight were pooled, behavioral interventions reduced fasting glucose by an average of 3.4 mg/dl more than control conditions (WMD= -3.4, 95% CI -5.5, -1.4, I2=82.8%, k=8, n=3,849; Figure 12), although with high statistical heterogeneity.” This figure is also described in “Results: Key Question 3: Pharmacotherapy: Orlistat: Effect of Orlistat on Glucose Tolerance” as follows: “Those randomized to orlistat experienced a 5.7 mg/dl greater reduction in fasting glucose over 12 months, compared to those given placebo (95% CI -8.3, -3.0, I2=79.6%, k=9; n=3,727; Figure 12).”

Figure 12Difference Between Intervention and Control Groups in Change in Plasma Glucose (mg/dL)

Abbreviations: CI=confidence interval; CV=cardiovascular; DPP=Diabetes Prevention Program; FDPS=Finnish Diabetes Prevention Study; HEED=Help Educate to Eliminate Diabetes; HI=intensive intervention; IV=intervention; LO=brief intervention; N=number; NR=not reported; PREDIAS=Prevention of Diabetes Self-Management Program; SD=standard deviation; Subclincl=subclinical; Unsel=unselected; WHLP=Women's Healthy Lifestyle Project; WMD=weighted mean difference.

From: 3, Results

Cover of Screening for and Management of Obesity and Overweight in Adults
Screening for and Management of Obesity and Overweight in Adults [Internet].
Evidence Syntheses, No. 89.
LeBlanc E, O'Connor E, Whitlock EP, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.